Medicine Blogs

Hair loss treatments are often described as if they all do the same job. They do not. Some slow the signals that shrink vulnerable follicles.

Mitochondria are often described as cellular power plants, but energy production is only part of their role. They also merge, divide, change shape, recycle damaged components, and communicate with the rest of the cell.

Growth hormone sounds like something we should want more of as we age. It helps children grow, supports protein synthesis, influences muscle and bone, and helps regulate how the body uses fat and glucose.

Mitochondria are often described as the powerhouses of the cell because they produce much of the energy cells use. Their role is broader, however: they also influence cell growth, stress signaling, inflammation, and programmed cell death.

Hydrogen is the smallest molecule in the universe, which has not prevented it from accumulating a remarkably large résumé. Molecular hydrogen—H2, not hydrogen peroxide, not hydrogen ions, and not the hydrogen already bound into ordinary water—is being studied as an inhaled medical gas and as hydrogen dissolved in water or saline.

The search for a longevity microbiome often sounds like a microbial shopping list: acquire more of one bacterial genus, suppress another, and perhaps buy a probiotic containing whatever name is currently fashionable. A new review argues that this may be the wrong level of biology.

Imagine renovating a house after a small indoor tornado. One crew removes the broken drywall, ruined wiring, and mysterious damp thing nobody wants to identify.

Most cancer drugs are built around a familiar idea: find a troublesome protein and block it. That can work brilliantly, but only when the protein has a pocket a drug can reach and when the cancer does not simply make more protein, alter the pocket, or route around the blockade.

Cancer drugs usually try to block, poison, or remove something the cancer cell needs. A new study in Cell explores a different strategy: use a small molecule to force two proteins together, then turn the cancer's own gene-control machinery against it.

Imagine inventing a fire extinguisher powerful enough to save a burning kitchen - and then installing the nozzle in every room, including the nursery and the neighbor's garage. This is roughly the predicament of many brilliant drugs.

Most of us learn a tidy division of labor in the immune system. CD4 T cells are the coordinators: they send instructions and help other immune cells respond.

Two people can have the same body mass index, or BMI, and very different metabolic health. One reason is where their fat is stored.

A car dashboard does not compress fuel level, oil pressure, engine temperature, and tire pressure into one mysterious number. Yet most biological-age tests do something similar: they take signals from across the body and report one overall estimate.

The phrase "stem cell therapy" can sound almost magical: collect versatile cells, place them into an injured body, and watch them rebuild whatever is broken. Mesenchymal stem cells, or MSCs, have attracted exactly this kind of attention.

Imagine a medicine that could switch on some of the molecular programs normally activated by exercise. For an older person confined by pain, injury, or illness, that possibility is genuinely important.

CRISPR is often described as a pair of molecular scissors that can rewrite DNA. Put that idea beside aging, and the imagination races: repair damaged genes, rejuvenate old cells, and perhaps add healthy years to life.

Coronary artery disease often advances for years without chest pain or another obvious warning. A coronary artery calcium scan can reveal one trace of that hidden process: calcium embedded within plaque in the walls of the heart's arteries.

The thymus has long been viewed as an immune organ that fades into retirement after childhood. A new Nature study using AI and chest CT scans suggests that healthier-looking adult thymic tissue is associated with longer survival and lower risks of lung cancer and cardiovascular death—but the findings remain observational.

Heart disease rarely comes from a single broken switch. It usually develops through several interacting problems: blood pressure, cholesterol, smoking, blood-sugar control, body composition, inflammation, genetics, and time. A 2025 study asked whether combining two of those signals, inflammation and insulin resistance, might reveal cardiovascular risk more clearly than looking at either one alone [1].

Uric acid has a public-relations problem. Most people meet it through gout, kidney stones, or a laboratory result their doctor wants to lower. Yet uric acid is also one of the most abundant antioxidants circulating in human blood.

Coffee headlines tend to arrive with the confidence of a barista calling out an order: three cups are good, five cups are bad, and your genes decide the rest. The real evidence is more interesting and less tidy. Two large UK Biobank studies found that moderate coffee intake was associated with lower risks at several stages of chronic disease, while one of them also found higher risks among people drinking more than five cups a day.

The compound that makes tomatoes red has attracted attention far beyond the produce aisle. Lycopene is a carotenoid, a family of plant pigments that includes several substances with antioxidant activity. In laboratory research, lycopene has shown intriguing effects in models of brain injury, including models designed to imitate selected features of Parkinson's disease.

Aging biology has a wonderfully unfair habit: just when you think the plot is about genes, stem cells, or mitochondria, it points to something duller and more physical, like old proteins quietly getting chemically scuffed. The new Nature Communications paper from Trabosh and colleagues is about exactly that sort of damage, and its central claim is preliminary but genuinely interesting: an engineered enzyme called CMLase can remove a common aging-related protein modification called N-epsilon-carboxymethyl-lysine, or CML, from model proteins and from aged human tissue samples outside the body [1]. That is not the same as rejuvenating a person.

GLP-1 drugs have changed what is possible in obesity treatment. Semaglutide and related medicines can produce weight loss that once required bariatric surgery. But the number on the scale does not tell the whole story. When body weight falls, some of the loss comes from fat and some comes from lean tissue - a category that includes skeletal muscle, organs, connective tissue, water, and glycogen.

Every few years, the wellness world finds a molecule and hands it a cape. Not a modest cardigan. A cape, flapping while someone on a podcast says “regeneration” like it is a sacrament. BPC-157 is one of those molecules. It is often called the “Wolverine peptide,” a warning sign because biology is not a Marvel franchise. The claim is seductive: faster tendon healing, calmer guts, less pain. Wonderful. Also: hold the parade. BPC-157 stands for Body Protection Compound-157. It is a short chain of amino acids, originally studied as a stable gastric pentadecapeptide - a 15-amino-acid fragment associated with stomach-related biology

A diabetes medicine has become one of the more interesting side stories in aging research. The drugs are called SGLT2 inhibitors, a mouthful of a name for medicines such as empagliflozin, dapagliflozin, and canagliflozin. They were first developed to help people with type 2 diabetes lower blood sugar. More recently, doctors have learned that some of these drugs can also protect the heart and kidneys. Now researchers are asking a newer question: could they also calm some of the cellular wear-and-tear linked with aging? A 2025 review in npj Aging argues that the idea is scientifically plausible, but still early [1].

Alzheimer's disease is usually discussed in terms of sticky amyloid plaques, tangled tau proteins, and the slow loss of memory. Those pieces still matter. But a new study adds another layer to the story: the way brain cells decorate proteins with sugar-based molecules. In a 2026 Nature Metabolism paper, researchers reported that brains affected by Alzheimer's disease showed unusually high levels of a process called glycosylation, and that pushing this process up or down changed memory-related behavior in mouse models [1].

Every cell in your body is a talker. Some cells communicate with electrical pulses, some with hormones, and many with tiny packages called extracellular vesicles, or EVs. Think of EVs as sealed envelopes released by cells into the fluid around them. Inside the envelope may be proteins, fats, pieces of genetic material, or chemical signals. Other cells can pick up these packages and change their behavior in response. That is useful when the message says, in effect, repair this tissue or calm this inflammation. It can be harmful when the message spreads stress, inflammation, or damaged cell parts.

Survodutide is not approved as a consumer treatment for fatty liver disease. That is the first bucket to keep the facts in. The second bucket is more interesting: a new phase 3 trial gives the drug a real reason to be watched closely. Phase 3 means the treatment has moved past small early studies and is being tested in a larger, more serious way before regulators decide what to do with it. The SYNCHRONIZE-MASLD study tested once-weekly survodutide, an injectable drug that turns on two body signaling systems: the glucagon receptor and the GLP-1 receptor. GLP-1 is the family of signals made famous by newer weight-loss and diabetes drugs. Glucagon is a different signal involved in how the body handles stored fuel. Put them together and you get a drug designed to push on weight, blood sugar, fat metabolism, and possibly the liver itself [1].

Artificial intelligence is not making aging disappear. Let's get that out of the way before the immortality kazoo parade starts honking its way down the hallway and somebody in a Patagonia vest tells you that death has been disrupted. It has not. Biology remains stubborn, damp, mutinous, and very fond of humiliating clean business plans. But AI is doing something real in longevity science: it is becoming a ferociously fast pattern-finder, the sort of tool that can rummage through genes, proteins, blood markers, medical records, imaging, drug structures, clinical trials, and wearable-device signals without needing coffee, tenure, or a sabbatical.

Most of us think about the body clock in ordinary terms: sleep, jet lag, late-night snacks, and the misery of daylight saving time. A 2026 Cell study takes that familiar idea into much deeper territory. Researchers reported that timed treatment with 3'-deoxyadenosine, also called 3dA or cordycepin, strengthened circadian rhythm amplitude in a small hypothalamic brain region called the paraventricular nucleus, or PVN. In aged male mice, that intervention improved several aging-related measures, reduced DNA-methylation age, restored hormonal synchrony, and extended lifespan

Rapamycin has become one of the most talked-about drugs in longevity circles. Depending on who is speaking, it is either the most promising geroprotector we have or a risky transplant drug being dragged too quickly into wellness culture. A 2026 randomized trial called RAPA-EX-01 gives the conversation something it badly needed: a real human result that was not especially flattering. In sedentary adults aged 65 to 85, weekly sirolimus, which is the medical name for rapamycin, did not improve the benefits of a 13-week exercise program. In some analyses, it may have slightly reduced gains in chair-stand performance, and the Sirolimus group had more adverse events

Let us begin with the fantasy, because the fantasy is doing most of the work here. You are tired. Your sleep is lousy. The gym used to reward you for showing up, and now it behaves like a bureaucrat who lost your paperwork. Then along comes sermorelin, a tidy little peptide with a lab-coat name and a seductive promise: nudge your pituitary, raise growth hormone, bring back some of the old biological swagger. Terrific. Also, hold on to your wallet and maybe your endocrine system.

If you hear the word “polyphenols” and immediately think “superfood marketing,” that reaction is fair. The term gets tossed around so often that it can sound like nutritional confetti. But polyphenols are real, and they matter. They are a large family of compounds made by plants, and they show up in foods many people already eat: berries, cocoa, tea, coffee, olives, extra-virgin olive oil, grapes, apples, onions, herbs, and many vegetables [1]. The honest question is not whether polyphenols exist or whether they can do interesting things in a lab. The real question is whether they help people live longer or age better.

Rapamycin, or sirolimus, has become one of the central drugs in the modern biology-of-aging conversation. The reason is simple: in animal studies it has repeatedly extended lifespan and improved several measures of late-life function, which is rare enough to command attention. That track record is why rapamycin moved from an interesting laboratory result to a serious human research question. The question now is not whether mTOR signaling matters in aging. It plainly does. The question is whether manipulating that pathway in people can improve healthspan in a way that is clinically meaningful and safe. Human evidence, as of May 4, 2026, is still early and mixed, but it is no longer speculative

Your immune system is basically a paranoid security guard, constantly patrolling your body and demanding to see everyone's credentials. Most of the time, this works beautifully—infected cells get escorted out, abnormal cells get eliminated, and you stay healthy.